(6-methoxy-5-methylpyrimidin-4-yl)methanol | 1494676-15-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (6-methoxy-5-methylpyrimidin-4-yl)methanol
• 英文别名: (6-Methoxy-5-methylpyrimidin-4-YL)methanol
• CAS: 1494676-15-1
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: SOTOXLABOOOCBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.29
• 重原子数：
  11.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.24
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (6-methoxy-5-methylpyrimidin-4-yl)methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以99%的产率得到4-(chloromethyl)-6-methoxy-5-methylpyrimidine
  参考文献：
  名称：

  AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME

  摘要：

  该发明提供了式（I）的化合物以及用于治疗结核分枝杆菌感染或肺结核，或者用于抑制DprE1的方法。

  公开号：

  US20150025087A1
• 作为产物：
  描述：

  草酰丙酸二乙酯 在 sodium tetrahydroborate 、 sodium ethanolate 、 三氯氧磷 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 18.0h， 生成 (6-methoxy-5-methylpyrimidin-4-yl)methanol
  参考文献：
  名称：

  AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME

  摘要：

  该发明提供了式（I）的化合物以及用于治疗结核分枝杆菌感染或肺结核，或者用于抑制DprE1的方法。

  公开号：

  US20150025087A1

文献信息

• AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME
  申请人：Global Alliance for TB Drug Development

  公开号：US20150025087A1

  公开（公告）日：2015-01-22

  The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.

  该发明提供了式（I）的化合物以及用于治疗结核分枝杆菌感染或肺结核，或者用于抑制DprE1的方法。
• CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20210292333A1

  公开（公告）日：2021-09-23

  Present invention relates to novel compound of general formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection. The compounds of general formula (I) exhibit DprE1 enzyme inhibitory activity.
• Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious <i>in Vivo</i>
  作者：Pravin S. Shirude、Radha Shandil、Claire Sadler、Maruti Naik、Vinayak Hosagrahara、Shahul Hameed、Vikas Shinde、Chandramohan Bathula、Vaishali Humnabadkar、Naveen Kumar、Jitendar Reddy、Vijender Panduga、Sreevalli Sharma、Anisha Ambady、Naina Hegde、James Whiteaker、Robert E. McLaughlin、Humphrey Gardner、Prashanti Madhavapeddi、Vasanthi Ramachandran、Parvinder Kaur、Ashwini Narayan、Supreeth Guptha、Disha Awasthy、Chandan Narayan、Jyothi Mahadevaswamy、KG Vishwas、Vijaykamal Ahuja、Abhishek Srivastava、KR Prabhakar、Sowmya Bharath、Ramesh Kale、Manjunatha Ramaiah、Nilanjana Roy Choudhury、Vasan K. Sambandamurthy、Suresh Solapure、Pravin S. Iyer、Shridhar Narayanan、Monalisa Chatterji

  DOI：10.1021/jm401382v

  日期：2013.12.12

  We report 1,4-azaindoles as a new inhibitor class that kills Mycobacterium tuberculosis in vitro and demonstrates efficacy in mouse tuberculosis models. The series emerged from scaffold morphing efforts and was demonstrated to noncovalently inhibit decaprenylphosphoryl-beta-D-ribose2'-epimerase (DprE1). With "drug-like" properties and no expectation of pre-existing resistance in the clinic, this chemical class has the potential to be developed as a therapy for drug-sensitive and drug-resistant tuberculosis.
• [EN] CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA<br/>[FR] COMPOSÉS AZAHÉTÉROARYLES CONDENSÉS AYANT UNE ACTIVITÉ ANTIBACTÉRIENNE CONTRE LES BACTÉRIES DE LA TUBERCULOSE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2019239382A1

  公开（公告）日：2019-12-19

  Present invention relates to novel compound of general formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection. The compounds of general formula (I) exhibit DprE1 enzyme inhibitory activity.

  本发明涉及一般式（I）的新化合物，它们的对映体、非对映体、药学上可接受的盐或其前药，适用于治疗细菌感染。一般式（I）的化合物表现出DprE1酶抑制活性。